Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular non-Hodgkin lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. It is not yet known whether ofatumumab and bendamustine hydrochloride are more effective with bortezomib in treating patients with follicular non-Hodgkin lymphoma.

Official Title

A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC # 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma

Details

Keywords

Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Lymphoma, Follicular Lymphoma, Deoxyglucose, Bortezomib, Bendamustine Hydrochloride, Ofatumumab, Fluorodeoxyglucose F18, Monoclonal Antibodies, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography with Radiolabeled Targeting Agent, ofatumumab, bendamustine hydrochloride, ofatumumab, bendamustine hydrochloride, bortezomib

Eligibility

Locations

  • UC San Diego Moores Cancer Center
    La Jolla California 92093 United States
  • Saint Helena Hospital
    Saint Helena California 94574 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
National Cancer Institute (NCI)
ID
NCT01286272
Phase
Phase 2 Lymphoma Research Study
Study Type
Interventional
Participants
About 135 people participating
Last Updated